Raymond James Financial Services Advisors Inc. Grows Stake in DexCom, Inc. (NASDAQ:DXCM)

Raymond James Financial Services Advisors Inc. grew its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 275.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 580,226 shares of the medical device company's stock after purchasing an additional 425,880 shares during the period. Raymond James Financial Services Advisors Inc. owned approximately 0.15% of DexCom worth $80,477,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Stableford Capital II LLC grew its position in DexCom by 2.1% in the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company's stock worth $563,000 after acquiring an additional 88 shares in the last quarter. D Orazio & Associates Inc. grew its position in DexCom by 0.8% in the fourth quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company's stock worth $1,534,000 after acquiring an additional 93 shares in the last quarter. Gulf International Bank UK Ltd grew its position in DexCom by 0.3% in the first quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company's stock worth $4,448,000 after acquiring an additional 93 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in DexCom by 10.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the medical device company's stock worth $133,000 after acquiring an additional 98 shares in the last quarter. Finally, Harbor Investment Advisory LLC grew its position in DexCom by 13.1% in the first quarter. Harbor Investment Advisory LLC now owns 864 shares of the medical device company's stock worth $120,000 after acquiring an additional 100 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on DXCM shares. StockNews.com upgraded shares of DexCom from a "hold" rating to a "buy" rating in a research report on Wednesday. Royal Bank of Canada assumed coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an "outperform" rating and a $165.00 price target for the company. Raymond James upped their price target on shares of DexCom from $151.00 to $160.00 and gave the company a "strong-buy" rating in a research report on Friday, April 26th. Canaccord Genuity Group upped their price target on shares of DexCom from $144.00 to $145.00 and gave the company a "buy" rating in a research report on Friday, April 26th. Finally, Citigroup upped their price target on shares of DexCom from $148.00 to $161.00 and gave the company a "buy" rating in a research report on Wednesday, April 3rd. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, DexCom presently has a consensus rating of "Moderate Buy" and an average price target of $141.67.

Insider Activity

In other news, EVP Sadie Stern sold 20,321 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the sale, the executive vice president now owns 80,441 shares in the company, valued at $10,747,722.01. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, EVP Sadie Stern sold 20,321 shares of the firm's stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total value of $2,715,088.81. Following the sale, the executive vice president now owns 80,441 shares in the company, valued at $10,747,722.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the firm's stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the completion of the sale, the executive vice president now owns 42,377 shares in the company, valued at approximately $5,839,974.37. The disclosure for this sale can be found here. Insiders have sold a total of 189,375 shares of company stock worth $25,530,859 over the last 90 days. 0.41% of the stock is currently owned by insiders.

DexCom Stock Down 1.2 %

Shares of NASDAQ DXCM traded down $1.51 on Wednesday, reaching $125.88. 2,916,465 shares of the company's stock traded hands, compared to its average volume of 3,055,031. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00. The business's 50 day simple moving average is $131.68 and its two-hundred day simple moving average is $119.57. The company has a market cap of $50.06 billion, a price-to-earnings ratio of 81.21, a price-to-earnings-growth ratio of 2.14 and a beta of 1.20. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The business had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. As a group, equities research analysts forecast that DexCom, Inc. will post 1.77 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.